Randomized trial investigates MRD negativity predictors, clinical outcomes in multiple myeloma patients after ASCT, suggesting significant implications.
Key Points
This study aims to identify predictors of measurable residual disease (MRD) negativity post-autologous stem cell transplantation (ASCT) and their impact on clinical outcomes in multiple myeloma.
Analyzed data from 814 patients achieving at least very good partial response post-ASCT from January 2016 to January 2023.
MRD assessed using next-generation flow cytometry with a sensitivity of 2.4x10−6.
Statistical analyses included odds ratios (OR) and hazard ratios (HR) to evaluate the significance of predictors and clinical outcomes.
48% of patients achieved MRD negativity post-ASCT.
Presence of t(11;14) and pre-transplant response less than complete remission were significant independent predictors of MRD positivity (OR 2.1, 95% CI 1.4-3.2; p<0.01).
MRD-positive patients had worse progression-free survival (HR 1.99, 95% CI 1.53-2.58; p<0.001) and overall survival (HR 1.62, 95% CI 1.10-2.28; p=0.009).